Trevi Therapeutics, Inc. Increase (Decrease) in Prepaid Expense
Trevi Therapeutics, Inc. (TRVI) reported Increase (Decrease) in Prepaid Expense of -$449.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2021-03-25
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2020-12-31 was -$625.00K.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2020-09-30 was -$204.00K.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2020-06-30 was $1.01M, a 22.73% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2020-03-31 was -$626.00K, a 372.17% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2020 was -$449.00K, a 284.77% decline from fiscal 2019.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2019 was $243.00K, a 81.93% decline from fiscal 2018.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2018 was $1.34M.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$829.00K derived: sum of 2 quarters · filed 2021-03-25 | $177.00K derived: sum of 3 quarters · filed 2021-03-25 | -$449.00K 10-K · filed 2021-03-25 |
| 2020-09-30 | -$204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $802.00K derived: sum of 2 quarters · filed 2020-11-12 | $176.00K 10-Q · filed 2020-11-12 | $31.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $380.00K 10-Q · filed 2020-08-13 | $235.00K derived: sum of 3 quarters · filed 2021-03-25 | -$909.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | -$626.00K 10-Q · filed 2020-05-07 | -$771.00K derived: sum of 2 quarters · filed 2021-03-25 | -$1.92M derived: sum of 3 quarters · filed 2021-03-25 | -$613.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.29M derived: sum of 2 quarters · filed 2021-03-25 | $13.00K derived: sum of 3 quarters · filed 2021-03-25 | $243.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $158.00K derived: sum of 2 quarters · filed 2020-11-12 | $388.00K 10-Q · filed 2020-11-12 | $233.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $1.53M 10-Q · filed 2020-08-13 | $1.38M derived: sum of 3 quarters · filed 2020-08-13 | $1.32M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $230.00K 10-Q · filed 2020-05-07 | $75.00K derived: sum of 2 quarters · filed 2020-05-07 | $16.00K derived: sum of 3 quarters · filed 2020-05-07 | $1.40M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$214.00K derived: sum of 2 quarters · filed 2020-03-16 | $1.17M derived: sum of 3 quarters · filed 2020-03-16 | $1.34M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.32M derived: sum of 2 quarters · filed 2019-11-14 | $1.50M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $1.56M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $176.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |